About Guanine nucleotide-binding protein subunit alpha-13
Guanine nucleotide-binding protein subunit alpha-13 (GNA13) is a protein
from Homo sapiens identified by UniProt accession
Q14344, 377 residues long.
MolForge cross-references it against 0 known binders and
88 disease associations.
Target properties
| Protein name | Guanine nucleotide-binding protein subunit alpha-13 |
| UniProt accession | Q14344 |
| Gene | GNA13 |
| Organism | Homo sapiens |
| Length | 377 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (88)
Diseases linked to this target (Open Targets).
- diffuse large B-cell lymphoma · score 0.38
- lymphoma · score 0.37
- neurodegenerative disease · score 0.37
- white matter microstructure measurement · score 0.29
- neuroimaging measurement · score 0.27
- reticulocyte count · score 0.25
- breast adenocarcinoma · score 0.23
- urinary bladder cancer · score 0.22
- brain measurement · score 0.21
- cortical thickness · score 0.21
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14344-F1 | alphafold | PREDICTED | 91.42 | — |
Amino-acid sequence (377 residues)
MADFLPSRSV LSVCFPGCLL TSGEAEQQRK SKEIDKCLSR EKTYVKRLVK ILLLGAGESG KSTFLKQMRI IHGQDFDQRA REEFRPTIYS NVIKGMRVLV DAREKLHIPW GDNSNQQHGD KMMSFDTRAP MAAQGMVETR VFLQYLPAIR ALWADSGIQN AYDRRREFQL GESVKYFLDN LDKLGEPDYI PSQQDILLAR RPTKGIHEYD FEIKNVPFKM VDVGGQRSER KRWFECFDSV TSILFLVSSS EFDQVLMEDR LTNRLTESLN IFETIVNNRV FSNVSIILFL NKTDLLEEKV QIVSIKDYFL EFEGDPHCLR DVQKFLVECF RNKRRDQQQK PLYHHFTTAI NTENIRLVFR DVKDTILHDN LKQLMLQ
Explore Guanine nucleotide-binding protein subunit alpha-13 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets